Mesalazine sustained-release granules

Aidisa slowly and continuously releases 5-aminosalicylic acid through the intestinal mucosa (small intestine, colon, and rectum), achieving an anti-inflammatory effect.

Mesalazine. Chemical name: 5-aminosalicylic acid Molecular weight: C7H7N03

Slow-release granules in bags.

Acute attacks of ulcerative colitis; prevention of relapses. Prevention of acute attacks in patients with Crohn's disease who have frequent attacks.

Oral: The contents of the bag should be swallowed without chewing. The following dosage is taken orally 3-4 times a day, which can be taken with meals and rinsed with a glass of water. Acute phase: 4g per day (equivalent to 8 bags) Remission phase: 1.5g per day (equivalent to 3 bags) Crohn's disease: 2g per day (equivalent to 4 bags)

Rare. Headache, nausea, vomiting and other symptoms may occur at the beginning of treatment. If the following symptoms occur, the drug must be discontinued: 1. Acute pancreatitis, leukopenia, but the above symptoms are extremely rare and the prognosis is good after discontinuation of the drug. 2. Pericarditis and myocarditis may occur in very few patients.

People who are allergic to salicylic acid preparations.

Precautions for children: This test has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: There is no relevant information on the use of this product by the elderly.

Drug interactions may occur if used with other drugs. Please consult your doctor or pharmacist for details.

Keep tightly closed in a dry place.

0.5g/bag

36 months

Shanghai Ethypharm Pharmaceuticals Co., Ltd.

• Founded in:

  1995-12-08

• Address:

  No. 278 Qianyun Road, south of No. 16 Bridge, 318 National Highway, Xujing, Qingpu District, Shanghai

• Tax NO.:

  913100006073339796

• Registered Funds:

  $6.5 million

• Website:

  Log in to view

• Email:

  Log in to view